[ePublic Notice Highlights] Celltrion Obtains FDA Approval for Vegzelma Sales (Morning Summary)

[Asia Economy Reporter Lee Jung-yoon] Celltrion announced on the 28th that it has obtained final sales approval from the U.S. Food and Drug Administration (FDA) for Vegzelma (CT-P16, Avastin biosimilar).

The company stated, "Sales in the United States will be conducted nationwide through Celltrion Healthcare, which is responsible for overseas marketing and distribution of Celltrion products," and added, "We will continue to apply for global approvals, and will submit a disclosure upon obtaining approval for this product in Korea."

The following are Celltrion's disclosure and other major disclosures released during the morning trading session.

▲ Korea Financial Group = Decided to acquire 1,520,000 shares of its subsidiary Korea Investment & Securities from SF Credit Partners in the U.S. for 214.7 billion KRW. The shareholding ratio after acquisition will be 75.10%.

▲ ITIYs = Withdrawal of decision to enter into a trust contract for acquiring treasury shares worth 1.5 billion KRW.

▲ Mirainano Tech = Decided to issue 10 billion KRW worth of anonymous, unsecured private exchangeable bonds (EB).

This content was produced with the assistance of AI translation services.